TABLE 5.

Multivariate analysis—risk factors for time to CLAD: Propensity matched pairs post conversion to everolimus.

Variable	Hazard ratio	p-value
EVE	1.34 (0.88–2.06)	0.176
Estimated GFR at time of starting EVE	1.01 (1.00–1.01)	0.143
% FVC predicted at time of starting EVE	0.99 (0.98–1.00)	0.007
Cystic Fibrosis	0.49 (0.25–0.97)	0.039
ISHLT graded ≥2 ACR a	2.30 (1.53–3.45)	0.0001
Mycophenolate	0.67 (0.44–1.01)	0.058

Abbreviations: ACR, acute cellular rejection; CLAD, chronic lung allograft dysfunction; EVE, everolimus; FVC, forced vital capacity; GFR, glomerular filtrate rate; ISHLT, international society for heart and lung transplantation.

^a Episode of ISHLT graded ≥2 ACR pre or post starting EVE.